24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Key Points

• The research aims to assess the real-world effectiveness of nemolizumab in providing itch relief and improving lesions in prurigo nodularis patients.
• 24-week analysis of prurigo nodularis patients receiving nemolizumab
• Evaluation of itch relief and lesion improvement over time
• Monitoring of adverse events affecting treatment adherence.
• Nemolizumab demonstrated rapid itch relief within the first weeks of treatment.
• Gradual improvement of skin lesions was noted during the 24-week period.
• Early response to pruritus may correlate with long-term treatment efficacy.